Literature DB >> 9192978

Abnormal expression of CCND1 and RB1 in resection margin epithelia of lung cancer patients.

D C Betticher1, J Heighway, N Thatcher, P S Hasleton.   

Abstract

Tumours develop through the accumulation of genetic alterations associated with a progressive increase of the malignant phenotype. In lung cancer, chronic exposure of bronchial epithelium to carcinogens in cigarette smoke may lead to multiple dysplastic and hyperplastic lesions scattered throughout the tracheobronchial tree. Little is known about the genetic alterations in such lesions. This study was carried out to examine cyclin D1 (CCND1) and retinoblastoma (RB1) gene expression in the bronchial epithelium of patients with lung cancer. Lung tumours and their corresponding tumour-free resection margins from 33 patients who underwent resection of non-small-cell lung cancer (NSCLC) were examined by immunostaining with monoclonal antibodies against cyclin D1 (DCS-6; Novocastra) and pRb (NCL Rb-1; Novocastra). Examination of the resection margins revealed four carcinomas in situ, 19 hyperplasias and ten sections showing apparently normal bronchial epithelium. A control group of patients, without lung tumours and who had never smoked, revealed no or weak cyclin D1 and positive pRb staining within bronchial epithelia. Increased cyclin D1 and diminished pRb expression were found in 76% (n = 25) and 27% (n = 9) of the resection margins respectively, and in 12% (n = 4) both cyclin D1 and pRb expression were altered. In the corresponding tumours, 48% (n = 16) were normal, while altered expression was found for cyclin D1 in 33% (n = 11), pRb in 27% (n = 9) and both in 9% (n = 3) of cases. It appears that altered expression of cyclin D1 and pRb is an early event in NSCLC development in almost half of cases analysed. Further investigations are needed to determine the significance of immunostaining of bronchial specimens in individuals at risk of lung cancer, with the possibility that the observations are of importance in the early diagnosis of NSCLC.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192978      PMCID: PMC2223623          DOI: 10.1038/bjc.1997.300

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  45 in total

Review 1.  The molecular genetics of lung cancer.

Authors:  D P Carbone; J D Minna
Journal:  Adv Intern Med       Date:  1992

2.  Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck.

Authors:  R Michalides; N van Veelen; A Hart; B Loftus; E Wientjens; A Balm
Journal:  Cancer Res       Date:  1995-03-01       Impact factor: 12.701

3.  Amplification and overexpression of the cyclin D1 gene in aggressive human hepatocellular carcinoma.

Authors:  N Nishida; Y Fukuda; T Komeda; R Kita; T Sando; M Furukawa; M Amenomori; I Shibagaki; K Nakao; M Ikenaga
Journal:  Cancer Res       Date:  1994-06-15       Impact factor: 12.701

4.  Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer.

Authors:  I E Schauer; S Siriwardana; T A Langan; R A Sclafani
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

5.  Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas.

Authors:  H J Xu; S X Hu; P T Cagle; G E Moore; W F Benedict
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

6.  Abnormalities in the PRAD1 (CYCLIN D1/BCL-1) oncogene are frequent in cervical and vulvar squamous cell carcinoma cell lines.

Authors:  R Kurzrock; S Ku; M Talpaz
Journal:  Cancer       Date:  1995-01-15       Impact factor: 6.860

7.  Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.

Authors:  C Gillett; V Fantl; R Smith; C Fisher; J Bartek; C Dickson; D Barnes; G Peters
Journal:  Cancer Res       Date:  1994-04-01       Impact factor: 12.701

8.  Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers.

Authors:  Y Kishimoto; K Sugio; J Y Hung; A K Virmani; D D McIntire; J D Minna; A F Gazdar
Journal:  J Natl Cancer Inst       Date:  1995-08-16       Impact factor: 13.506

9.  Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

Authors:  J Bartkova; J Lukas; M Strauss; J Bartek
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

10.  Monoclonal antibody against PRAD1/cyclin D1 stains nuclei of tumor cells with translocation or amplification at BCL-1 locus.

Authors:  S Banno; K Yoshikawa; S Nakamura; K Yamamoto; T Seito; M Nitta; T Takahashi; R Ueda; M Seto
Journal:  Jpn J Cancer Res       Date:  1994-09
View more
  10 in total

Review 1.  Clinico-prognostic value of D-type cyclins and p27 in laryngeal cancer patients: a review.

Authors:  L Pignataro; G Sambataro; D Pagani; G Pruneri
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-04       Impact factor: 2.124

2.  Neuroepithelial bodies of pulmonary airways serve as a reservoir of progenitor cells capable of epithelial regeneration.

Authors:  S D Reynolds; A Giangreco; J H Power; B R Stripp
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Cell cycle suppressor proteins are not related to HPV status or clinical outcome in patients with vulvar carcinoma.

Authors:  André Mourão Lavorato-Rocha; Iara Sant'ana Rodrigues; Beatriz de Melo Maia; Mônica Maria Ágata Stiepcich; Glauco Baiocchi; Kátia Cândido Carvalho; Fernando Augusto Soares; José Vassallo; Rafael Malagoli Rocha
Journal:  Tumour Biol       Date:  2013-07-06

4.  EGFR/erB-1, HER2/erB-2, CK7, LP34, Ki67 and P53 expression in preneoplastic lesions of bronchial epithelium: an immunohistochemical and genetic study.

Authors:  Vítor Sousa; Joana Espírito Santo; Maria Silva; Teresa Cabral; Ana Maria Alarcão; Ana Gomes; Patrícia Couceiro; Lina Carvalho
Journal:  Virchows Arch       Date:  2011-03-22       Impact factor: 4.064

5.  Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis.

Authors:  Jianming Liu; Qiande Liao; Yangde Zhang; Shenghua Sun; Caigao Zhong; Xinmin Liu
Journal:  Tumour Biol       Date:  2012-04-24

Review 6.  Cyclin D1 and human neoplasia.

Authors:  R Donnellan; R Chetty
Journal:  Mol Pathol       Date:  1998-02

7.  Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer.

Authors:  Clay E S Comstock; Michael A Augello; Ruth Pe Benito; Jason Karch; Thai H Tran; Fransiscus E Utama; Elizabeth A Tindall; Ying Wang; Craig J Burd; Eric M Groh; Hoa N Hoang; Graham G Giles; Gianluca Severi; Vanessa M Hayes; Brian E Henderson; Loic Le Marchand; Laurence N Kolonel; Christopher A Haiman; Raffaele Baffa; Leonard G Gomella; Erik S Knudsen; Hallgeir Rui; Susan M Henshall; Robert L Sutherland; Karen E Knudsen
Journal:  Clin Cancer Res       Date:  2009-08-25       Impact factor: 12.531

8.  The cyclin D1 (CCND1) G870A polymorphism and lung cancer susceptibility: a meta-analysis.

Authors:  Changxi Zhou; Huaijie An; Mingdong Hu; Qinghui Liu; Peiliang Geng; Jiancheng Xu; Baojun Sun; Changting Liu
Journal:  Tumour Biol       Date:  2013-07-20

9.  Cyclin D1 overexpression, p16 loss, and pRb inactivation play a key role in pulmonary carcinogenesis and have a prognostic implication for the long-term survival in non-small cell lung carcinoma patients.

Authors:  Na-Hye Myong
Journal:  Cancer Res Treat       Date:  2008-06-30       Impact factor: 4.679

10.  Direct progression of capsular invasive carcinomas from subcapsular focal hyperplasias induced by hypothyroidism-mediated tumor promotion in a rat two-stage thyroid carcinogenesis model.

Authors:  Kyohei Ago; Sayaka Kemmochi; Reiko Morita; Atsunori Yafune; Ayako Shiraki; Kunitoshi Mitsumori; Makoto Shibutani
Journal:  J Cancer Res Clin Oncol       Date:  2012-11-01       Impact factor: 4.553

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.